
Sign up to save your podcasts
Or


In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study:
Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016
Panelists:
By Dr. Cush4.7
121121 ratings
In this journal club, we will discuss two pivotal studies in ILD, the FIBRONEER study and the RECITAL study:
Nerandomilast in Patients with Progressive Pulmonary Fibrosis, Maher, T.M. et al. NEJM. 2025 May 19. doi: 10.1056
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial, Maher T.M., et al. Lancet 2023 Jan;11(1). doi: 10.1016
Panelists:

701 Listeners

504 Listeners

264 Listeners

3,374 Listeners

1,150 Listeners

122 Listeners

120 Listeners

194 Listeners

518 Listeners

367 Listeners

68 Listeners

5 Listeners

183 Listeners

19 Listeners

6 Listeners